Authors: Ying Yang Zhenlong Wu Sichao Jia Sudath Dahanayaka Shuo Feng Cynthia J Meininger Catherine J McNeal Guoyao Wu
Publish Date: 2015/05/07
Volume: 47, Issue: 9, Pages: 1909-1920
Abstract
This study was conducted with rats to determine the safety of longterm dietary supplementation with larginine Beginning at 6 weeks of age male and female rats were fed a caseinbased semipurified diet containing 061 larginine and received drinking water containing larginineHCl 0 18 or 36 g larginine/kg bodyweight/day n = 10/group These supplemental doses of larginine were equivalent to 0 286 and 573 mg larginine/kg bodyweight/day respectively in humans After a 13week supplementation period blood samples were obtained from rats for biochemical analyses Supplementation with larginine increased plasma concentrations of arginine ornithine proline homoarginine urea and nitric oxide metabolites without affecting those for lysine histidine or methylarginines while reducing plasma concentrations of ammonia glutamine free fatty acids and triglycerides lArginine supplementation enhanced protein gain and reduced whitefat deposition in the body Based on general appearance feeding behavior and physiological parameters all animals showed good health during the entire experimental period Plasma concentrations of all measured hormones except leptin did not differ between control and argininesupplemented rats lArginine supplementation reduced plasma levels of leptin Additionally larginine supplementation increased larginineglycine amidinotransferase activity in kidneys but not in the liver or small intestine suggesting tissuespecific regulation of enzyme expression by larginine Collectively these results indicate that dietary supplementation with larginine eg 36 g/kg bodyweight/day is safe in rats for at least 91 days This dose is equivalent to 40 g larginine/kg bodyweight/day for a 70kg person Our findings help guide clinical studies to determine the safety of longterm oral administration of larginine to humans
Keywords: